Sensitive tear screening of diabetic retinopathy with dual biomarkers enabled using a rapid electrokinetic patterning platform

Wang, Jen Yi; Kwon, Jae‐Sung; Hsu, Sheng Min; Chuang, Huey-Ru

doi:10.1039/c9lc00975b

Cited by 24 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For independent validation cohort, we achieved sensitivity of 90%, specificity of 83% with an AUC of 0.926 (black curve in Figure 4c‐ii), which was superior to the results reported using other molecular tools, such as GC MS (AUC = 0.739; n = 183), [ 41 ] nano‐electrospray ionization (nano‐ESI) MS (accuracy = 82.00%; n = 52), [ 42 ] and immunosensing (accuracy = 88.46%; n = 24). [ 43 ] In comparison, the diagnostic model built on the plasma MFs outperformed the traditional CM, which demonstrated an AUC of 0.718 and 0.700 in discovery and validation cohorts respectively (red curves in Figure 4c). Importantly, the performance of fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) alone only afforded an AUC of 0.650 and 0.700 in validation cohort (Figure S11a,b, Supporting Information), known as the epidemiological risk factors of DR recommended by American Diabetes Association (ADA) [ 44 ] and World Health Organization (WHO).…”

Section: Resultsmentioning

confidence: 99%

Vanadium Core–Shell Nanorods Inspect Metabolic Changes of Diabetic Retinopathy

Vedarethinam

Huang

Zhang

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and ranks as the fifth leading cause of visual impairment, but an understanding of DR development has been hampered by the lack of an efficient metabolomic tool. Herein, vanadium core–shell nanorods are developed for metabolic fingerprinting to probe molecular variation in DR. First, a series of vanadium core–shells are constructed with different elemental composition and structural parameters, using silica nanorods to support vanadium oxide. The plasma metabolic fingerprints (MFs) are extracted by the optimized vanadium core–shell nanorod‐assisted laser desorption/ionization mass spectrometry, by analyzing 500 nL of native plasma in seconds. As a result, DR patients are differentiated from non DR controls with a sensitivity of 94% and specificity of 90% using a classification model built on the plasma MFs. Furthermore, DR progression is monitored by a panel of plasma metabolic signatures with gradual changes. This work provides an advanced molecular tool for the metabolomic characterization of DR and may guide the clinical decision making in DR for personalized medicine in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Vanadium Core–Shell Nanorods Inspect Metabolic Changes of Diabetic Retinopathy

Vedarethinam

Huang

Zhang

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…The results demonstrated high specificity and linear dose-dependent responses. 68 A LOD of 100 pg mL −1 was achieved with a broad range of measurement over five orders of magnitude using only 1.5 μL of tear sample. A chip sensitivity of 92.9%, specificity of 90.9%, and accuracy of 88.5% were achieved with thresholds of 250 μg mL −1 and 10 ng mL −1 for LCN1 and VEGF, respectively.…”

Section: Lab-on-a-chip Platforms For Biomarker Detection In Diabetic ...mentioning

confidence: 98%

Lab-on-a-chip technologies for minimally invasive molecular sensing of diabetic retinopathy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover, VEGF165 levels also significantly differ in various stages of human disease. For example, the serum of patients with diabetes, non-proliferative diabetic retinopathy, and proliferative diabetic retinopathy contains higher levels of VEGF165 compared with serum from healthy individuals ( Manaviat et al, 2011 ; Ahuja et al, 2019 ; Abu-Yaghi et al, 2020 ; Wang et al, 2020 ). Therefore, accurate, sensitive, and rapid detection of the disease-specific biomarker VEGF165 in bodily fluids may serve as an effective tool for healthcare monitoring as well as disease diagnosis and prognosis.…”

Section: Introductionmentioning

confidence: 99%

A Fluorescent Aptasensor Based on Assembled G-Quadruplex and Thioflavin T for the Detection of Biomarker VEGF165

Zheng

Gao

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

VEGF165, a regulator of angiogenesis, has been widely used as a serum biomarker for a number of human diseases, including cancer, rheumatoid arthritis, bronchial asthma, and diabetic eye disease. The rapid, accurate, and convenient detection of VEGF165 is a crucial step in effective healthcare monitoring, disease diagnosis, and prognosis assessment. In this study, a fluorescent aptasensor based on an assembled G-quadruplex and the signal molecule ThT was developed for VEGF165 detection. First, G-rich DNA fragments were assembled at both ends of the anti-VEGF165 aptamer, and the B-DNA form was converted into a G-quadruplex structure aptamer (G4-Apt). Then, ThT was introduced, and the G-quadruplex significantly enhanced the fluorescence intensity of the bound ThT. When VEGF165 was present, the higher affinity of the aptamer to the target protein allowed the G4-Apt/VEGF165 complex to form and release ThT, which emitted only weak fluorescence in the free state. Therefore, the aptasensor exhibited a good linear detection window from 1.56 to 25 nM VEGF165, with a limit of detection of 0.138 nM. In addition, the aptasensor was applied to detect VEGF165 in clinical serum samples, showing good accuracy, reproducibility, and stability. These results indicate that our developed fluorescent aptasensor can potentially be a reliable, convenient, and cost-effective approach for the sensitive, specific, and rapid detection of the VEGF165 biomarker.

show abstract

Sensitive tear screening of diabetic retinopathy with dual biomarkers enabled using a rapid electrokinetic patterning platform

Abstract: A screening technique with dual biomarkers for diabetic retinopathy (DR) based on optoelectrokinetics was presented. Our technique will revolutionize the diagnostic method for DR and enable an early treatment to improve patients' quality of life.

Cited by 24 publications

References 33 publications

Vanadium Core–Shell Nanorods Inspect Metabolic Changes of Diabetic Retinopathy

Vanadium Core–Shell Nanorods Inspect Metabolic Changes of Diabetic Retinopathy

Lab-on-a-chip technologies for minimally invasive molecular sensing of diabetic retinopathy

A Fluorescent Aptasensor Based on Assembled G-Quadruplex and Thioflavin T for the Detection of Biomarker VEGF165

Contact Info

Product

Resources

About